COMMUNIQUÉS West-GlobeNewswire

FDA Issues Nyxoah an Approvable Letter for its Genio® System
26/03/2025
INSIDE INFORMATION REGULATED INFORMATION FDA Issues Nyxoah an Approvable Letter for its Genio® System Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ [...]
La FDA Délivre à Nyxoah une Lettre d'Approuvabilité pour son système Genio®
26/03/2025
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES La FDA Délivre à Nyxoah une Lettre d'Approuvabilité pour son Système Genio® Mont-Saint-Guibert, Belgique – 26 mars 2025, 8h00 CET / 3h00 ET – Nyxoah SA (Euronext [...]
Pleco Therapeutics Announces Positive Outcome of Pre-IND meeting with FDA for PTX-252 in Acute Myeloid Leukaemia
26/03/2025
NIJMEGEN, The Netherlands, March 26, 2025 (GLOBE NEWSWIRE) -- Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, announces a positive outcome from [...]
ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Designed to Restore Standing, Stepping, and Lower Limb Mobility
26/03/2025
The ARC-IM Lumbar Lead is the second model in the ARC-IM Lead family to be used in a clinical feasibility study The Company is building a portfolio of purpose-designed leads to optimize delivery of ARC-IM Therapy at [...]
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
26/03/2025
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertility A phase 1/2 [...]
Communiqué de presse : La FDA des États-Unis accorde une procédure accélérée au candidat-vaccin contre les infections à Chlamydia
26/03/2025
La FDA des États-Unis accorde une procédure accélérée au candidat-vaccin contre les infections à Chlamydia Les infections à Chlamydia peuvent contribuer à l’apparition d’inflammations pelviennes chez la femme et être à [...]
BioVersys Reports Corporate Highlights and Key Financials for the Full Year 2024
26/03/2025
BASEL, Switzerland, March 26, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy data Alpibectir: Phase 2a EBA trial [...]
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
26/03/2025
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, [...]
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
26/03/2025
ROCKVILLE, Md. and SUZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to [...]
Biomea Fusion Announces Leadership Transition
26/03/2025
Board member Mick Hitchcock named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc [...]
Dr. Thierry Jacquemin Expands His Innovative Approach to Health, Performance, and Aesthetic Wellness
25/03/2025
Renowned physician enhances personalized wellness solutions with advanced treatments in anti-aging, performance optimization, and regenerative medicine MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- As demand for [...]
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
25/03/2025
SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics [...]
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
25/03/2025
New, improved formulation set to replace EGRIFTA SV ® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage [...]
Theratechnologies reçoit l’approbation de la FDA pour EGRIFTA WR(MC) (la formulation F8 de la tésamoréline) pour traiter l’excès de graisse viscérale abdominale chez les adultes vivant avec le VIH atteints de lipodystrophie
25/03/2025
Une nouvelle formulation améliorée remplacera EGRIFTA SV MD MONTRÉAL, 25 mars 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société [...]
Genmab Announces Initiation of Share Buy-Back Program
25/03/2025
Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billion Reduce the capital of Genmab and honor our commitments under the Restricted Stock Unit program [...]
ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
25/03/2025
Marseille, France, March 25, 2025 4:30 p.m. EST/21:30 CET– ImCheck Therapeutics announced today it will present updated results from its ongoing open-label, randomized Phase I/II study EVICTION at the American [...]
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
25/03/2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Blueberries Medical Announces C$1 Million Non-Brokered Private Placement
25/03/2025
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the " Company " or " Blueberries "), a Latin American licensed producer of medicinal cannabis and cannabis- [...]
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
25/03/2025
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three additional posters [...]

Pages